Slide 1: Trading update for the four months ended 30 April 2026
21 May 2026 Trading update for the four months ended 30 April 2026
Slide 2: Important notice and forward-looking statements
For the purposes of this notice, “Presentation” means this document, its contents or any part of it, any oral presentation, any question or answer session and any written or oral material discussed or distributed before, during or after the Presentation meeting. This information, which does not purp
Slide 3: Hosts
Hosts Jonny Mason Fiona Ryder Chief Executive Officer Chief Financial Officer 4 convatec
Slide 4: Organic revenue growth by category, Jan-Apr 2026
Unchanged Jan-Apr 2026 FY26 guidance • Continued broad-based growth Organic revenue growth1 4.8%2 5-7%2 • Growth expected to accelerate in H2 given customer ex-InnovaMatrix2 order phasing and as product launches build Advanced Wound Care • Growth led by LATAM & APAC, with solid Europe MSD2 MSD2 ex-I
Slide 5: FY26 guidance unchanged
• Unchanged guidance for each category: AWC: MSD Organic revenue Unchanged growth1 ex-InnovaMatrix2 5-7% FY25: 6.4% ex-InnovaMatrix; OC: MSD; CC: MSD; IC: HSD • InnovaMatrix: estimate around $20m revenue Adjusted operating Unchanged • Further operations, commercial & G&A productivity profit margin ≥
Slide 6: Category highlights and product launches
Advanced Wound Care Ostomy Care • ConvaFoam continued to gain share • Esteem Body performing strongly and winning share • Rich pipeline: ConvaNiox, ConvaFiber & ConvaVAC • Flexi-Seal Air launching in 2026; Natura Body in 2027 • Continued Aquacel growth • GPO wins – Premier Inc / Premier AscenDrive C
Slide 7: Business performing well and in-line with expectations
• Business performing well and in-line with expectations • Broad-based growth across all categories • New product launches winning share • 5-7% organic revenue growth1 ex-InnovaMatrix2 • ≥ 23.0% adjusted operating profit margin, including c.(40) bps FX headwinds • Double-digit adjusted EPS growth, w
Slide 8: &
&